Aflapin demonstrated to provide fast-acting symptomatic treatment of knee OA .
A double blind, randomized, placebo controlled clinical study evaluates the early efficacy of aflapin in subjects with osteoarthritis of knee
Int J Med Sci. 2011;8(7):615-22. Epub 2011 Oct 1260 patients were randomized to investigate the effect of Alfapin supplementation in the treatment of knee osteoarthritis. In the 30-day trial, patients were randomized to receive either Alfapin 50mg twice daily or placebo, and were followed-up with assessments of pain, stiffness, and physical function. Serum, urine, and hematological characteristics were also assessed for safety analysis. The results at 30 days indicated that pain, stiffness, and function were significantly improved with Alfapin, and that differences in improvement were observed as early as 5 days after commencing supplementation. Furthermore, laboratory tests indicated serum, urine and hematological properties remained within normal ranges.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
